You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays.
Pharma locks in on North Carolina
The pharmaceutical industry has lost some longtime allies in recent years. By the looks of it, executives and lobbyists are looking to North Carolina to make some new ones, according to federal campaign finance disclosures. Recall that a freshman Democratic lawmaker from North Carolina, Rep. Don Davis, was willing to stick his neck out and sponsor a policy to water down Democrats’ drug pricing reform bill earlier this year.
Another North Carolina Democrat caught industry’s eye last quarter: Rep. Deborah Ross, who is a member of House Democratic leadership as chief deputy whip and is on the caucus’ steering and policy committee. Ross received campaign donations in May from the CEOs of Merck, Eli Lilly, Biogen, Gilead, Bristol Myers Squibb, Genentech, and UCB, as well as a donation from PhRMA’s COO and PAC contributions from Eisai and Genentech.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect